Company intelligence / Profile preview

gpASIT

Brussels, Belgium

Ownership: Private
Employees: ~22
Development stage: Other

Overview

gp-ASIT+™ demonstrated significant improvements in grass pollen allergic rhinitis symptoms (15–21% reduction in combined symptom/medication score) and good tolerability in a real-life, multicenter Phase III trial involving 554 patients across Europe. The main published clinical studies confirmed its efficacy, mechanism (induction of blocking IgG4 antibodies), and safety.

Therapeutic areas: Immunology
Modalities: Allergen extractBiologicPeptides
Industry: Biotech

Partnerships

Collaborations with Imperial College London (Dr. Mohamed Shamji—mechanism of action studies, immunological research)

Beyond the preview

Go deeper on gpASIT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gpASIT.

Explore the full profile